16
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T10863 | Complement C5-IN-1 | Complement System | |
Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5). | |||
T9915 | Eculizumab | Complement System | |
Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5 | |||
T76867 | Ravulizumab | ALXN1210 | Complement System |
Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity to block complement activation. Ravulizumab can be used fo... | |||
T77022 | Gefurulimab | ||
Gefurulimab (ALXN-1720) is a bispecific antibody derived from humans, targeting complement C5 and albumin. It specifically binds to C5, inhibiting its activation [1]. | |||
T74431 | Cemdisiran | ||
Cemdisiran, a conjugated siRNA with N-acetylgalactosamine (GalNAc), targets the liver to inhibit the production of complement 5 (C5) protein, serving as a potential therapeutic agent for the study of complement-mediated ... | |||
T75106 | ARC186 | ||
ARC186 is a highly potent aptamer that serves as a complement inhibitor by blocking the convertase-catalyzed activation of C5. | |||
T74551 | Avacincaptad pegol sodium | ||
Avacincaptad pegol (ARC1905), an anti-C5 RNA aptamer, prevents the cleavage of complement factor 5 (C5) into fragments C5a and C5b. It is currently under investigation for the treatment of age-related macular degeneratio... | |||
T76276 | Zilucoplan | ||
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor, is utilized in the study of immune-mediated necrotising myopathy (IMNM) [1] [2]. | |||
T77121 | Pozelimab | ||
Pozelimab (REGN3918), a fully human IgG4 monoclonal antibody, is designed to target and bind with high affinity to both C5 and its variants, effectively inhibiting complement-mediated hemolysis. It holds potential for re... | |||
T74552 | Non-PEGylated/naked ARC1905 | ||
ARC1905, a non-PEGylated/naked anti-C5 RNA aptamer, functions by inhibiting the cleavage of complement factor 5 (C5) into its components, C5a and C5b, without PEG conjugation. This compound is currently being researched ... | |||
T74550 | Cemdisiran, terminal sugar modification- | ||
Cemdisiran, an investigational N-acetylgalactosamine-conjugated RNAi (RNA interference) agent with terminal sugar modification, is a small interfering RNA (siRNA) designed to specifically target and suppress the C5 mRNA,... | |||
T77190 | Crovalimab | ||
Crovalimab (SKY59; RO7112689) is a novel humanized antibody designed to target C5 in a pH-dependent manner, demonstrating binding affinities (KD) of 15.2 nM and 16.8 μM at pH levels of 7.4 and 5.8, respectively. Addition... | |||
T80083 | Zilucoplan TFA | RA101495 TFA | Complement System |
Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, serves as a potent inhibitor of complement component 5 (C5). It has applications in the study of immune-mediated necrotising myopathy (IMNM) [1] [2]. | |||
T78191 | NH2-C6-ARC186 | Complement System | |
NH2-C6-ARC186 is a derivative of the aptamer ARC186, featuring an NH2-C6 moiety that enables coupling to various peptides or molecules. As a potent complement inhibitor, it operates by inhibiting convertase-mediated C5 a... | |||
T77163 | Pexelizumab | ||
Pexelizumab (h5G1.1-SC), a humanized scFv monoclonal antibody, targets the C5 complement component, thereby inhibiting apoptosis and leukocyte infiltration. It is utilized in researching cerebral ischemia-reperfusion (IR... | |||
T74699 | Avacincaptad pegol | ||
Avacincaptad pegol, a pegylated aptamer, stands out as an effective C5 complement inhibitor capable of mitigating inflammation-induced damage to the retinal pigment epithelium (RPE). This compound is under investigation ... |